At Rubedo Life Sciences, we developed a novel concept of intelligent discovery platform combined with recombinant chemistry to selectively target specific cell types of the body, without toxicity or side effects.
The first product line developed by Rubedo labs is based on smart molecules that can target a population of pro-inflammatory cells that accumulate in the body with age, called “Senescent Cells”. These cells cause increased chronic inflammation, pain, and tissue decay that contribute to age-related diseases like Diabetes, Alzheimer’s, Cardio-Vascular Diseases and Cancer.
By selectively clearing the body of these cells, while preserving adjacent healthy cells, the tissues start to rejuvenate and diseases revert to improved healthy states.
The first of our therapeutic approaches is designed to target these senescent cells (which are normally locked in their cell cycle state called G0) by inducing them to die through a mechanism called apoptosis. By doing so, the body will be specifically cleared of these senescent cells without affecting the other healthy cells present in our bodies.
The consequence of this are rejuvenative effects that restores health.
Our initial indications are:
As a result of any cancer standard of care treatments (such as chemotherapy and radiotherapy), tissues in the body will accumulate a large number of senescent cells. The pro-inflammatory environment created by senescent cells promotes tissue decay and the inherent toxicity of the cancer treatments create additional side effects. Patients struggle with longer recovery and higher morbidity following conventional therapies.
Rubedo Life Sciences is developing small molecules engineered to selectively clear senescent and cancer cells from the body at the same time, offering improved efficacy, reduced toxicity and fewer side effects. As a result, patients will experience more efficacy in cancer treatments, improved recovery and a higher quality of life.
Older or sick people exposed to toxic and aging factors such as pollution, smoking, viruses and infections, develop a number of often lethal respiratory conditions. By rejuvenating lung tissues with our targeted strategy that treat the biological drivers of these pathologies our treatments will prevent the dramatic consequences of these degenerative diseases.
Other pipelines in the discovery phase focus on targeting other cell types other than senescence cells, such as stem cells to activate their regenerative potential, progressively lost with age and diseases.